CU6 - Media and Industry News, page-404

whoever is analysing for UBS, I'm worried. Their points to address, from my viewpoint:

1. Cu6 can image at both timepoints. And why would you not want to image next day when it is significantly better and picking up malignancy that isn't picked up via already approved modality?

3. Most clinicians have openly stated that current SoC cannot pick up lesions <4-5mm. If clarity can pick up lesions from 2mm, and this is shown in BCR P2 to pick up significantly more malignancies, I think it's pretty concerning. Early detection = better outcomes.

4. While late players having low share is true, but I believe having such a superior product over competitors will overcome this issue

5. I feel both are saying contrasting comments. Who is telling the truth?

Going by all the GUro videos going around, it seems like lots of clinicians are quite excited about cu64/67. That's a concern in itself.